ICU患者手术部位感染发生率与手术抗菌药物预防:一项多中心观察性研究
这项在法国5个ICU开展的回顾性多中心队列研究(2022年3月至2023年3月)纳入338例ICU停留≥48小时且期间接受手术的成人患者,主要终点为术后SSI发生率。总体SSI发生率为21%;手术时存在疑似感染(PATOS)者SSI发生率为37%,PATOS阴性者为18%。调整预设混杂因素后,广谱vs窄谱抗菌药物与SSI相关(OR 3.06;95%CI 1.63-5.76;P<0.001),无抗菌药物vs窄谱抗菌药物亦相关(OR 2.49;95%CI 1.01-6.15;P=0.048)。SSI与ICU/住院时间延长、器官支持使用增加及第28天和第90天结局更差相关。
要点
- ICU期间手术患者总体SSI发生率为21%,手术时存在疑似感染(PATOS)者SSI发生率达37%,PATOS阴性者为18%。
- 调整预设混杂因素后,无抗菌药物覆盖vs窄谱抗菌药物与SSI风险增加独立相关(OR 2.49;95%CI 1.01-6.15;P=0.048)。
- 广谱vs窄谱抗菌药物与SSI的关联(OR 3.06;95%CI 1.63-5.76;P<0.001)可能反映适应证混杂,不宜解读为广谱药物导致SSI。
- SSI与ICU/住院时间延长、器官支持使用增加及第28天和第90天结局更差相关。
- 基于非ICU人群的传统SAP指南可能不适用于危重患者,需ICU特异性预防策略及前瞻性研究。
适用人群与场景
- 法国5个ICU的成人患者(≥18岁),ICU停留≥48小时且ICU期间接受手术,纳入2022年3月至2023年3月。
诊断标准与关键阈值
- 手术部位感染(SSI)为术后发生的手术部位感染。
- 手术时存在疑似感染(PATOS)定义为手术时怀疑存在感染(原文未给出具体判定标准),本研究中52例(15%)为PATOS阳性。
处置流程与药物剂量
- 原文未提及具体药物、剂量、给药途径、频次或疗程;SAP定义为切皮前给予针对清洁或清洁-污染手术可能病原体的抗菌药物,且手术部位无活动性感染。
- 原文未提及ICU特异性预防流程或目标值。
红旗征与不能漏的情况
- 手术时存在疑似感染(PATOS)者SSI发生率达37%,需警惕术后SSI。
- SSI与ICU/住院时间延长、器官支持使用增加及第28天和第90天结局更差相关。
研究设计与关键结果
- 研究类型:回顾性多中心队列研究,5个法国ICU,纳入338例患者(中位年龄56岁,IQR 35-67;72%男性)。
- 主要终点:总体SSI发生率为21%;PATOS阳性(n=52,15%)SSI发生率37%,PATOS阴性18%。
- 调整后关联:广谱vs窄谱抗菌药物OR 3.06(95%CI 1.63-5.76;P<0.001);无抗菌药物vs窄谱抗菌药物OR 2.49(95%CI 1.01-6.15;P=0.048)。
- 分层分析显示抗菌药物谱对PATOS阳性和创伤患者的SSI风险也有显著影响。
- SSI与ICU/住院时间延长、器官支持使用增加及第28天和第90天结局更差相关。
证据类型、等级与局限
- 证据类型:回顾性多中心观察性队列研究。
- 局限:回顾性设计、样本量338例、仅5个中心、观察性研究存在混杂(作者指出广谱抗菌药物关联可能为适应证混杂)。
对床旁实践的改变
- 在ICU期间手术的危重患者中,应警惕SSI风险(总体21%,PATOS阳性者37%),术后需加强监测。
- 避免无抗菌药物覆盖下的手术预防;但广谱抗菌药物与SSI的关联可能为适应证混杂,不应据此常规选择广谱药物。
- 传统基于非ICU人群的SAP指南可能不适用于危重患者,需ICU与手术室团队协调并发展ICU特异性预防策略。
- 适用人群为ICU停留≥48小时且期间手术的成人;原文未提及不适用人群。
指南或共识出处
- 原文未提及具体指南或共识名称;仅提及传统SAP指南来源于非ICU人群。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Surgical site infection (SSI) is a major cause of postoperative morbidity. Surgical antibiotic prophylaxis (SAP), defined as the pre-incision administration of an antimicrobial agent targeting likely organisms in clean or clean-contaminated procedures without active infection at the operative site, is a cornerstone of prevention in surgery. However, critically ill patients represent a distinct population with profound susceptibility to infection. Data on SSI incidence and SAP practices in patients undergoing surgery during an intensive care unit (ICU) stay remain scarce.
METHODS: Retrospective multicenter cohort study in five French ICUs (March 2022-March 2023). Adult patients (≥18 years) with an ICU stay ≥ 48 h who underwent surgery during their ICU stay were included. Primary outcome was SSI incidence after surgery. Generalized estimating equations (GEE) with a prespecified adjustment set were used to estimate the adjusted association between antimicrobial spectrum and SSI, accounting for clustering within centers.
RESULTS: 338 patients were included (median age 56 years, IQR 35 - 67; 72% male). Overall SSI incidence was 21%. Procedures with suspected infection present at time of surgery (PATOS) (n = 52, 15%) had an SSI incidence of 37%, against 18% in PATOS-negative patients. In the primary adjusted GEE analysis, broad-spectrum vs. narrow-spectrum antimicrobials (OR 3.06; 95%CI 1.63-5.76; P < 0.001) and no antimicrobial vs. narrow-spectrum antimicrobials (OR 2.49; 95%CI 1.01-6.15; P = 0.048) were independently associated with SSI. Stratified analysis showed that antimicrobial spectrum also had significant effect on SSI risk on PATOS-positive and trauma patients. SSI was associated with prolonged ICU/hospital length of stay, increased organ support use, and worse outcomes at day 28 and day 90.
CONCLUSIONS: SSI affects more than one in five critically ill patients. After adjustment for prespecified confounders, the association with broad-spectrum therapy likely reflected confounding by indication, whereas the absence of any antimicrobial coverage was independently associated with increased SSI risk. Conventional SAP guidelines derived from non-ICU populations may not apply to critically ill patients. ICU-specific prophylactic strategies, improved coordination between ICU and operating room teams, and prospective studies are needed to enhance SSI prevention in this high-risk population.
参考来源
- Pastene B, Chemli N, Dudoignon E, et al. Surgical site infection incidence and surgical antibiotic prophylaxis in the ICU patient: a multicenter observational study. J Intensive Care. 2026. PMID: 42661230. doi:10.1186/s40560-026-00916-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。